|Bid||72.46 x 100|
|Ask||74.25 x 100|
|Day's range||74.14 - 76.33|
|52-week range||55.80 - 83.49|
|PE ratio (TTM)||12.48|
|Earnings date||27 Feb 2018|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||81.88|
Jan.09 -- Express Scripts CEO Tim Wentworth discusses mergers and acquisitions in the healthcare industry. He speaks with Bloomberg's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.
Jan.09 -- Express Scripts CEO Tim Wentworth discusses the value of pharmacy benefit managers. He speaks with Bloomberg's Erik Schatzker at the J.P. Morgan Healthcare Conference in San Francisco.
ST. LOUIS and DEERFIELD, Ill., Feb. 20, 2018 /PRNewswire/ -- Express Scripts Holding Company (ESRX) and Walgreens Boots Alliance, Inc. (WBA) today announced they are expanding their group purchasing efforts to include the procurement of specialty brand drugs. Given the savings potential associated with biosimilars in the coming years, the two companies believe this expansion is particularly timely. "Specialty medications represent the most costly and complex drugs. By expanding our efforts with Walgreens Boots Alliance, we will improve our supply chain and ultimately make the use of these medicines, including biosimilars, more affordable and accessible for our patients and clients," said Express Scripts President and CEO Tim Wentworth.
FRANKLIN LAKES, N.J., Feb. 20, 2018 /PRNewswire/ -- Pet parents of dogs, cats, hamsters, reptiles and even monkeys can now more easily afford their pet's prescribed medications with the Inside Rx PetsSM discount card, which can offer an average savings of 75 percent off generics and up to 15 percent off brand medications. Costs for managing your pet's health can be a bear with pet owners spending more than $8 billion on prescription and over-the-counter medications annually.
An Irish drugmaker has put a price tag of almost $3,000 on a bottle of two-in-one painkillers that can be bought separately for $36, in another instance of gouging in the US, the world’s largest healthcare ...
ST. LOUIS , Feb. 6, 2018 /PRNewswire/ -- At a time when consumers, businesses and policymakers are intensely focused on reducing prescription drug costs, Express Scripts (NASDAQ: ESRX) helped employers ...
FRANKLIN LAKES, N.J., Feb. 5, 2018 /PRNewswire/ -- Inside Rx today announced that it is now offering better pricing on the brand and generic versions of Tamiflu® (oseltamivir phosphate) to help Americans affected by what the Centers for Disease Control and Prevention (CDC) has called the worst recorded influenza season in almost a decade. Launched last year by Express Scripts (ESRX), the Inside RxSM prescription savings program can provide deeper savings to people who pay full-list price for prescription medications.
Investors seemed unsure which health-care stock to sell first, after today’s announcement of a medical cost-containment venture by Berkshire Hathaway (ticker:ticker::BRK.A), Amazon.com (AMZN), and JPMorgan Chase (JPM). The three firms gave few details about how they’ll try to cut their medical bills, but this morning’s selloff implied that Wall Street fears most for the profits of pharmacy businesses like Express Scripts Holding (ESRX), and health insurers like Cigna (CI) and Anthem (ANTM). It’s a good guess that the trio will start by targeting pharmacy spending and the profit margins of Express Scripts, CVS Health (CVS), and Walgreens Boots Alliance (WBA) as have other employer alliances aimed at health-care costs.
Amazon, Berkshire Hathaway and JPMorgan announce plans to partner on ways to cut health care costs and improve services for U.S. employees.
- Inside Rx Generated $35 Million in Savings Since May 2017 - 30 new brand medications for weight loss, dermatology, gastrointestinal conditions and allergies now available FRANKLIN LAKES, N.J. , Jan. ...
Louis, Jan. 15, 2018-- Express Scripts Holding Company announced today its intention to release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018, after the market closes ...
WASHINGTON, Jan. 11, 2018 /PRNewswire/ -- During a briefing on meaningful solutions for safer opioid prescribing with Congressional Representatives Ann McLane Kuster (D-NH) and Tom MacArthur (R-NJ), Express Scripts (ESRX) today announced that an initial 90-day review of its Advanced Opioid ManagementSM program shows that the comprehensive solution is protecting people using an opioid medication, particularly those taking an opioid for the first time. In the first 90 days since the program began on September 1, 2017, the company observed a nearly 60 percent reduction in the average days supply for patients receiving an opioid prescription for the first time, from 18.6 days supply per prescription claim before the launch of the program, to 7.5 days supply per claim after the start of the program.
ST. LOUIS , Jan. 10, 2018 /PRNewswire/ -- Accredo ® specialty pharmacy, a subsidiary of Express Scripts (NASDAQ: ESRX), has earned URAC's specialty pharmacy accreditation at its primary dispensing locations: ...
FRANKLIN LAKES, N.J. , Jan. 10, 2018 /PRNewswire/ -- Inside Rx, which administers a prescription savings program for the uninsured and underinsured, is helping more people access savings to prescription ...
Express Scripts shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.
Small biotech firm Spark Therapeutics (ONCE) recently announced a new gene therapy that is designed to treat a rare, inherited retinal disease that can cause blindness. Approved by the FDA, Luxturna costs $425,000 per eye, or $850,000 for both
The price is for Spark Therapeutics' Luxturna, approved by the FDA in December to treat a rare, inherited retinal disease that can lead to blindness.
ST. LOUIS , Jan. 2, 2018 /PRNewswire/ -- Express Scripts Holding Company (Nasdaq: ESRX) (" Express Scripts ") announced today that it will present at the J.P. Morgan Healthcare Conference on ...